血必净注射液联合乌司他丁注射液治疗重症脓毒症休克患者的临床研究
发布时间：2018-11-22 11:53
【摘要】：目的观察血必净注射液联合乌司他丁注射液治疗重症脓毒症休克的临床疗效及安全性。方法将68例重症脓毒症休克患者随机分为对照组34例和试验组34例。对照组予以静脉滴注血必净50 mL,bid;试验组在对照组治疗的基础上,联合静脉滴注乌司他丁60万U,bid。2组患者均治疗2周。比较2组患者的临床疗效、临床指标、生化指标、死亡率及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为91.18%(31/34例)和88.24%(30/34例),差异无统计学意义(P0.05)。治疗后,试验组和对照组的C反应蛋白分别为(24.56±4.21)和(48.21±5.22)mg·L~(-1),降钙素原分别为(1.04±0.21)和(2.88±0.45)ng·mL~(-1),白细胞分别为(8.75±2.12)×109和(13.48±3.45)×109/L,脑钠肽分别为(0.54±0.05)和(0.87±0.15)ng·mL~(-1),肌钙蛋白T分别为(0.35±0.03)和(0.76±0.18)ng·mL~(-1),肌钙蛋白Ⅰ分别为(0.42±0.07)和(0.87±0.24)ng·mL~(-1),肌酸激酶同工酶分别为(14.57±2.41)和(18.79±3.52)U·L~(-1),乳酸分别为(2.65±0.46)和(5.21±1.04)nmol·L~(-1),机械通气时间分别为(10.21±1.56)和(18.22±3.87)d,住院时间分别为(16.09±2.45)和(24.33±4.53)d,差异均有统计学意义(均P0.05)。试验组和对照组各发生皮疹1例,差异无统计学意义(P0.05)。试验组和对照组的死亡率分别为5.88%和26.47%,差异有统计学意义(P0.05)。结论血必净注射液联合乌司他丁注射液治疗重症脓毒症休克的临床疗效与单用血必净注射液相当,但前者能明显改善患者的生化指标,缩短住院时间,降低死亡率,且不增加药物不良反应发生率。
[Abstract]:Objective to observe the efficacy and safety of Xuebijing injection combined with ulinastatin injection in the treatment of severe septic shock. Methods 68 patients with severe septic shock were randomly divided into control group (n = 34) and experimental group (n = 34). The patients in the control group were treated with intravenous drip of Xuebijing 50 mL,bid; on the basis of the control group, and the patients in the control group were treated with ulinastatin 600000 Ubid.2 intravenous drip for 2 weeks. The clinical efficacy, clinical indexes, biochemical indexes, mortality and adverse drug reactions were compared between the two groups. Results after treatment, the total effective rates of the experimental group and the control group were 91.18% (31 / 34 cases) and 88.24% (30 / 34 cases), respectively. The difference was not statistically significant (P0.05). After treatment, C-reactive protein and procalcitonin were (24.56 卤4.21) and (48.21 卤5.22) mg L ~ (-1), (1.04 卤0.21) and (2.88 卤0.45) ng mL~ (-1), respectively. WBC were (8.75 卤2.12) 脳 109 and (13.48 卤3.45) 脳 109 / L, brain natriuretic peptide were (0.54 卤0. 05) and (0. 87 卤0. 15) ng mL~ (-1), respectively. Troponin T was (0.35 卤0.03) and (0.76 卤0.18) ng mL~ (-1), troponin 鈪，
本文编号：2349301
[Abstract]:Objective to observe the efficacy and safety of Xuebijing injection combined with ulinastatin injection in the treatment of severe septic shock. Methods 68 patients with severe septic shock were randomly divided into control group (n = 34) and experimental group (n = 34). The patients in the control group were treated with intravenous drip of Xuebijing 50 mL,bid; on the basis of the control group, and the patients in the control group were treated with ulinastatin 600000 Ubid.2 intravenous drip for 2 weeks. The clinical efficacy, clinical indexes, biochemical indexes, mortality and adverse drug reactions were compared between the two groups. Results after treatment, the total effective rates of the experimental group and the control group were 91.18% (31 / 34 cases) and 88.24% (30 / 34 cases), respectively. The difference was not statistically significant (P0.05). After treatment, C-reactive protein and procalcitonin were (24.56 卤4.21) and (48.21 卤5.22) mg L ~ (-1), (1.04 卤0.21) and (2.88 卤0.45) ng mL~ (-1), respectively. WBC were (8.75 卤2.12) 脳 109 and (13.48 卤3.45) 脳 109 / L, brain natriuretic peptide were (0.54 卤0. 05) and (0. 87 卤0. 15) ng mL~ (-1), respectively. Troponin T was (0.35 卤0.03) and (0.76 卤0.18) ng mL~ (-1), troponin 鈪，
本文编号：2349301
本文链接：https://www.wllwen.com/linchuangyixuelunwen/2349301.html
最近更新
教材专著
